Galapagos: Triple combination advances, positive read-across (LLY/ROG)

BUY, Fair Value EUR52 (+30%)
News published on October Thursday 15, 2015
Share on

GLPG’s development for its triple combo advances well with the nomination of a second corrector for pre-clinical studies. The companies also identified other 2nd generation corrector series which might fuel the company’s CF pipeline in the upcoming months. We see two positive read-acrosses from (i) LLY’s JAK-inhibitor, baricitinib, which topped Humira in a phase III study and (ii) Roche’s BD activities in the auto-immune field with a promising early-stage pipeline which should not however allow the Pharma to fill its late stage pipeline with two blockbusters coming off-patent in 2018 and 2019.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities